4//SEC Filing
Watanabe Todd Franklin 4
Accession 0001787306-25-000050
CIK 0001787306other
Filed
Mar 25, 8:00 PM ET
Accepted
Mar 26, 4:41 PM ET
Size
12.4 KB
Accession
0001787306-25-000050
Insider Transaction Report
Form 4
Watanabe Todd Franklin
DirectorSee Remarks
Transactions
- Sale
Common Stock
2025-03-24$17.52/sh−1,500$26,282→ 927,414 total - Sale
Common Stock
2025-03-25$17.56/sh−2,171$38,131→ 925,243 total
Holdings
- 24,413(indirect: By Trust)
Common Stock
- 24,413(indirect: By Trust)
Common Stock
- 57,358(indirect: By LLC)
Common Stock
- 124,956(indirect: By Trust)
Common Stock
Footnotes (7)
- [F1]The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 14, 2024, by the Reporting Person, with a plan end date of September 30, 2025.
- [F2]The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $17.50 to $17.63, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $17.51 to $17.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F4]The securities are held of record by The John Franklin Watanabe Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
- [F5]The securities are held of record by The Anderson Prest Watanabe Irrevocable Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
- [F6]The securities are held of record by Watanabe Ventures, LLC, of which the Reporting Person is the Chief Operating Officer. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
- [F7]The securities are held of record by The Watanabe 2016 Irrevocable Trust, of which the Reporting Person's children are beneficiaries. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
Documents
Issuer
Arcutis Biotherapeutics, Inc.
CIK 0001787306
Entity typeother
Related Parties
1- filerCIK 0001801061
Filing Metadata
- Form type
- 4
- Filed
- Mar 25, 8:00 PM ET
- Accepted
- Mar 26, 4:41 PM ET
- Size
- 12.4 KB